Antiretroviral treatment changes in adults from Côte d'Ivoire: The roles of tuberculosis and pregnancy

AIDS

Volumn 24, Issue 1, 2010, Pages 93-99

  Messou, Eugène ^a,b   Anglaret, Xavier ^a   Duvignac, Julien ^a   Konan N'Dri, Eric ^b   Komena, Eric ^b   Gnokoro, Joachim ^b   Karcher, Sophie ^a   Tanoh, Anthony ^c   N'Dri Yoman, Thérèse ^b   Seyler, Catherine ^a  

^a INSERM   (France)

^b Association Aconda   (United States)

^c ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

Author keywords

Adults; Antiretroviral treatment; Efavirenz; Modification; Nevirapine; Pregnancy; Sub Saharan Africa; Tolerance; Tuberculosis

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; ETHAMBUTOL; INDINAVIR; ISONIAZID; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; COTE D'IVOIRE; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; TUBERCULOSIS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COTE D'IVOIRE; DRUG SUBSTITUTION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TUBERCULOSIS; VIRAL LOAD;

EID: 73649089307     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832ec1c3     Document Type: Article

References (29)

1. UNAIDS, WHO. 2007 AIDS epidemic update: sub-Saharan Africa regional summary. http://data.unaids.org/pub/Report/ 2008/jc1526-epibriefs-ssafrica-en. pdf.
2. WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report. 2008. http://www.who.int/hiv/pub/towards-universal- access-report-2008.pdf.
3. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10, 000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 2008; 22:873-882.
4. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782-793.
5. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367:1335-1342.
6. Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 2008; 168:86-93.
7. Wester CW, Kim S, BussmannH, Avalos A, Ndwapi N, Peter TF, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005; 40:336-343.
8. Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007; 12:753-760.
9. Forna F, Liechty CA, Solberg P, Asiimwe F, Were W, Mermin J, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007; 44:456-462.
10. Seyler C, Adje-Toure C, Messou E, Dakoury-Dogbo N, Rouet F, Gabillard D, et al. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS 2007; 21:1157-1164.
11. Anglaret X, Messou E, Ouassa T, Toure S, Dakoury-Dogbo N, Combe P, et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS 2003; 17:575-584
12. WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2003 revision. http://www.who.int/hiv/pub/prev-care/en/arvre-vision2003en.pdf.
13. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002; 51:1-55.
14. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007; 21:2483-2491.
15. Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis 2007; 44:141-144 (Pubitemid 44969000)
16. WHO. Antiretroviral therapy for HIV infection in adults and adolescents in ressource-limited settings: towards universal access. Recommendations for a public health approach. 2006 revisions. http://www.who.int/hiv/pub/guidelines/ WHO%20 Adult%20ART%20Guidelines.pdf.
17. Danel C, Moh R, Anzian A, Abo Y, Chenal H, Guehi C, et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr 2006; 42:29-35.
18. Bussmann H, Wester CW, Wester CN, Lekoko B, Okezie O, Thomas AM, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. J Acquir Immune Defic Syndr 2007; 45:269-273.
19. Loko MA, Toure S, Dakoury-Dogbo N, Gabillard D, Leroy V, Anglaret X. Decreasing incidence of pregnancy by decreasing CD4 cell count in HIV-infected women in Cote d'Ivoire: a 7-year cohort study. AIDS 2005; 19:443-445.
20. Harries AD, Schouten EJ, Makombe SD, Libamba E, Neufville HN, Some E, et al. Ensuring uninterrupted supplies of antire-troviral drugs in resource-poor settings: an example from Malawi. Bull World Health Organ 2007; 85:152-155.
21. Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med 2007; 4:e257.
22. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I. CO. N. A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14:499-507. (Pubitemid 30209692)
23. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Reasons for modification and discontinuation of antire-trovirals: results from a single treatment centre. AIDS 2001; 15:185-194.
24. Kirk O, Gerstoft J, Pedersen C, Nielsen H, Obel N, Katzenstein TL, et al. Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. HIV Med 2001; 2:43-51.
25. Smith CJ, Sabin CA, Lampe FC, Shah S, Tyrer M, Youle MS, et al. The relationship between CD4 cell count nadirs and the toxicity profiles of antiretroviral regimens. Antivir Ther 2005; 10:459-467.
26. Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antire-troviral therapy. J Acquir Immune Defic Syndr 2007; 46:451-455.
27. Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD. Modificationof the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005; 40:148-157.
28. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxa-zole in Cote d'Ivoire. Antivir Ther 2005; 10:615-624.
29. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004; 38 (Suppl 2):S80-89.